Abstract:Irene Rivero-Calle, 1, 2 Peter Francis Raguindin, 2 Jose Gómez-Rial, 2 Carmen Rodriguez-Tenreiro, 2 Federico Martinón-Torres 1, 2 1 Translational Pediatrics and Infectious Diseases, Department of Pediatrics, Hospital Clínico Universitario de Santiago de Compostela, Galicia, Spain; 2 Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Hospital Clínico Universitario and Universidad de Santiago de Compostela (USC), Galicia, Spain Correspondence: Federico Martinón-Torres Translational Pediatrics and Infectious Diseases Section, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela, Travesía da Choupana, s/n, Santiago de Compostela 15706, Spain Email Federico.Martinon.Torres@sergas.es Invasive meningococcal disease (IMD) is a major public health concern because of its high case fatality, long-term morbidity, and potential to course with outbreaks. IMD caused by Nesseira meningitidis serogroup B has been predominant in different regions of the world like Europe and only recently broadly protective vaccines against B serogroup have become available. Two protein-based vaccines, namely 4CMenB (Bexsero ® ) and rLP2086 (Trumenba ® ) are currently licensed for use in different countries against MenB disease. These vaccines came from a novel technology on vaccine design (or antigen selection) using highly specific antigen targets identified through whole-genome sequence analysis. Moreover, it has the potential to confer protection against non-B meningococcus and against other Neisserial species such as gonococcus. Real-world data on the vaccine-use are rapidly accumulating from the UK and other countries which used the vaccine for control of outbreak or as part of routine immunization program, reiterating its safety and efficacy. Additional data on real-life effectiveness, long-term immunity, and eventual herd effects, including estimates on vaccine impact for cost-effectiveness assessment are further needed. Given the predominance of MenB in Europe and other parts of the world, these new vaccines are crucial for the prevention and public health control of the disease, and should be considered. Keywords: meningococcal disease, invasive meningococcal disease, meningococcal B, vaccine development, vaccine effectiveness, epidemiology

World Experience in the Use Serogroup B Meningococcal Vaccines (literature review)

Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles

Routine vaccination against MenB

Challenges and progress in the development of a serogroup B meningococcal vaccine

A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB‐FHbp

Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines

Product review on the IMD serogroup B vaccine Bexsero®

A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB)

Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults

Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B

Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme

Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention.

The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.

Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review

Impact of meningococcal group B OMV vaccines, beyond their brief

Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection

Global incidence of serogroup B invasive meningococcal disease: a systematic review

Policies for the immunization against serogroup B meningococcus for adolescents immunized during the first two years of life: A mini review

A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program

Promising developments in gonococcal vaccines

From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine